VPRBP Functions Downstream of the Androgen Receptor and OGT to Restrict P53 Activation in Prostate Cancer

Overview

Journal Mol Cancer Res

Specialty Cell Biology

Date 2022 Mar 29

PMID 35348747

Authors

Ninu Poulose

Nicholas Forsythe

Adam Polonski

Gemma Gregg

Sarah Maguire

Marc Fuchs

Sarah Minner

Guido Sauter

Simon S McDade

Ian G Mills

Affiliations

Soon will be listed here.

Abstract

Implications: In conclusion, we have shown that VPRBP/DCAF1 promotes prostate cancer cell proliferation by restraining p53 activation under the influence of the AR and OGT.

Citing Articles

The roles of OGT and its mechanisms in cancer.

Liu X, Wang J, Xiang Y, Wang K, Yan D, Tong Y Cell Biosci. 2024; 14(1):121.

PMID: 39285476 PMC: 11406787. DOI: 10.1186/s13578-024-01301-w.

Glucose deprivation triggers DCAF1-mediated inactivation of Rheb-mTORC1 and promotes cancer cell survival.

Li M, Huang W, Zhang Y, Du Y, Zhao S, Wang L Cell Death Dis. 2024; 15(6):409.

PMID: 38862475 PMC: 11166663. DOI: 10.1038/s41419-024-06808-1.

Integrating single-cell RNA-sequencing and bulk RNA-sequencing data to explore the role of mitophagy-related genes in prostate cancer.

Liu Z, Huang R Heliyon. 2024; 10(9):e30766.

PMID: 38774081 PMC: 11107114. DOI: 10.1016/j.heliyon.2024.e30766.

DCAF1 interacts with PARD3 to promote hepatocellular carcinoma progression and metastasis by activating the Akt signaling pathway.

Zhang J, Shi Y, Ding K, Yu W, He J, Sun B J Exp Clin Cancer Res. 2024; 43(1):136.

PMID: 38711082 PMC: 11071249. DOI: 10.1186/s13046-024-03055-2.

Liu S, Guo T, Hu J, Huang W, She P, Wu Y AIDS Res Ther. 2023; 20(1):66.

PMID: 37691100 PMC: 10493029. DOI: 10.1186/s12981-023-00563-7.

References

Karimian A, Ahmadi Y, Yousefi B . Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage. DNA Repair (Amst). 2016; 42:63-71. DOI: 10.1016/j.dnarep.2016.04.008. View

Yang W, Kim J, Nam H, Ju J, Kim H, Kim Y . Modification of p53 with O-linked N-acetylglucosamine regulates p53 activity and stability. Nat Cell Biol. 2006; 8(10):1074-83. DOI: 10.1038/ncb1470. View

Wang G, Jones S, Marra M, Sadar M . Identification of genes targeted by the androgen and PKA signaling pathways in prostate cancer cells. Oncogene. 2006; 25(55):7311-23. DOI: 10.1038/sj.onc.1209715. View

Sollinger H . Mycophenolate mofetil. Kidney Int Suppl. 1995; 52:S14-7. View

Thul P, Akesson L, Wiking M, Mahdessian D, Geladaki A, Blal H . A subcellular map of the human proteome. Science. 2017; 356(6340). DOI: 10.1126/science.aal3321. View

Gu Y, Rosenblatt J, MORGAN D . Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and Tyr15. EMBO J. 1992; 11(11):3995-4005. PMC: 556910. DOI: 10.1002/j.1460-2075.1992.tb05493.x. View

Kamigaito T, Okaneya T, Kawakubo M, Shimojo H, Nishizawa O, Nakayama J . Overexpression of O-GlcNAc by prostate cancer cells is significantly associated with poor prognosis of patients. Prostate Cancer Prostatic Dis. 2013; 17(1):18-22. DOI: 10.1038/pcan.2013.56. View

Yang X, Qian K . Protein O-GlcNAcylation: emerging mechanisms and functions. Nat Rev Mol Cell Biol. 2017; 18(7):452-465. PMC: 5667541. DOI: 10.1038/nrm.2017.22. View

Le Rouzic E, Belaidouni N, Estrabaud E, Morel M, Rain J, Transy C . HIV1 Vpr arrests the cell cycle by recruiting DCAF1/VprBP, a receptor of the Cul4-DDB1 ubiquitin ligase. Cell Cycle. 2007; 6(2):182-8. DOI: 10.4161/cc.6.2.3732. View

10.

Kim K, Kim J, Kim J, Choi J, Suk Lee Y, Neamati N . VprBP has intrinsic kinase activity targeting histone H2A and represses gene transcription. Mol Cell. 2013; 52(3):459-67. PMC: 3851289. DOI: 10.1016/j.molcel.2013.09.017. View

11.

Barfeld S, Fazli L, Persson M, Marjavaara L, Urbanucci A, Kaukoniemi K . Myc-dependent purine biosynthesis affects nucleolar stress and therapy response in prostate cancer. Oncotarget. 2015; 6(14):12587-602. PMC: 4494960. DOI: 10.18632/oncotarget.3494. View

12.

Lindqvist A, van Zon W, Rosenthal C, Wolthuis R . Cyclin B1-Cdk1 activation continues after centrosome separation to control mitotic progression. PLoS Biol. 2007; 5(5):e123. PMC: 1858714. DOI: 10.1371/journal.pbio.0050123. View

13.

Gu Y, Gao J, Han C, Zhang X, Liu H, Ma L . O-GlcNAcylation is increased in prostate cancer tissues and enhances malignancy of prostate cancer cells. Mol Med Rep. 2014; 10(2):897-904. DOI: 10.3892/mmr.2014.2269. View

14.

Sammons M, Zhu J, Drake A, Berger S . TP53 engagement with the genome occurs in distinct local chromatin environments via pioneer factor activity. Genome Res. 2014; 25(2):179-88. PMC: 4315292. DOI: 10.1101/gr.181883.114. View

15.

Takayama K, Kaneshiro K, Tsutsumi S, Horie-Inoue K, Ikeda K, Urano T . Identification of novel androgen response genes in prostate cancer cells by coupling chromatin immunoprecipitation and genomic microarray analysis. Oncogene. 2007; 26(30):4453-63. DOI: 10.1038/sj.onc.1210229. View

16.

Schabla N, Mondal K, Swanson P . DCAF1 (VprBP): emerging physiological roles for a unique dual-service E3 ubiquitin ligase substrate receptor. J Mol Cell Biol. 2018; 11(9):725-735. PMC: 6821201. DOI: 10.1093/jmcb/mjy085. View

17.

Hattab E, Koch M, Eble J, Lin H, Cheng L . Tertiary Gleason pattern 5 is a powerful predictor of biochemical relapse in patients with Gleason score 7 prostatic adenocarcinoma. J Urol. 2006; 175(5):1695-9. DOI: 10.1016/S0022-5347(05)00998-5. View

18.

Swamy M, Pathak S, Grzes K, Damerow S, Sinclair L, van Aalten D . Glucose and glutamine fuel protein O-GlcNAcylation to control T cell self-renewal and malignancy. Nat Immunol. 2016; 17(6):712-20. PMC: 4900450. DOI: 10.1038/ni.3439. View

19.

Stark C, Breitkreutz B, Reguly T, Boucher L, Breitkreutz A, Tyers M . BioGRID: a general repository for interaction datasets. Nucleic Acids Res. 2005; 34(Database issue):D535-9. PMC: 1347471. DOI: 10.1093/nar/gkj109. View

20.

Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, Mesirov J . Molecular signatures database (MSigDB) 3.0. Bioinformatics. 2011; 27(12):1739-40. PMC: 3106198. DOI: 10.1093/bioinformatics/btr260. View